Method for efficiently detecting anti-retina antibody in serum and application thereof

Abstract

The invention relates to a method for efficiently detecting an anti-retina antibody (ARAs) in serum, which comprises the following steps: (1) extracting venous blood of a clinical suspected AIR patient, and centrifuging to obtain the serum of the patient; (2) taking retinal protein extracted from normal human retinal tissue homogenate as a reaction substrate, and detecting the number of antibody positive bands, namely the number of ARAs, in serum of a patient by adopting a western blot method; (3) with known human recombinant protein antigen as a reaction substrate, detecting and confirming ARAs types existing in serum of a patient by adopting a western blot method; (4) detecting the ARAs in the serum of the patient by adopting an immunofluorescence method, and positioning the ARAs in the normal human retina tissue slice to obtain the positioning of the ARAs in the serum of the patient in the retina tissue; and (5) according to the detection results of the ARAs in the serum of the patient obtained in the steps (2), (3) and (4), determining the number of the ARAs in the serum, the types of the ARAs in the serum and the positioning of the ARAs in the retina tissue, and establishing serological indexes of the clinical suspected AIR patient. The detection method disclosed by the invention is high in sensitivity and specificity and suitable for clinical early detection.

Description

Technical field [0001] The present invention belongs to the field of biomedical medicine, and in particular to a method of highly detecting serum antibody and its application thereof. Background technique [0002] Autoimmune Retinopathy, AIR is a class of immunfuminated blind eye diseases, including Paraneoplastic, P-Air and non-Paraneoplastic, NP- AIR) two major types. The clinical manifestations of Air of AIR include the loss of bindess painless subacute vision, ERG abnormal, serum in the serum - Anti-Retinal Antibodies, ARAS. P-AIR includes cancer-associated retinopathy, car-associated retinopathy, a melanoma-associated retinopathy melanoma-associated retinopathy, mar). Certain benign tumors also cause CAR-like changes. NP-AIR patients have not found tumors in patients, but are often accompanied by autoimmune diseases. At present, it is believed that AIR's pathogenesis is closely related to the existence of ARAS in serum. Due to external factors such as tumors or viruses, bact...

AI Technical Summary

Problems solved by technology

[0003] At present, there is no uniform serological testing standard for AIR in the world. There are a large number of potential patients, and delays in treatment or blind treatment due to missed diagnosis and misdiagnosis are common.

Based on the limitations of previous studies, such as small sample size, small number of detected ARAs, and single detection method, it is necessary to propose a new detection method for ARAs in the serum of clinically suspected AIR patients.

Images